



# The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023

Stockholm, Sweden - August 11, 2023 - Biosergen AB ("Biosergen" or the "Company") completed a rights issue of units on Nasdaq First North Growth Market in October 2022 (the "Rights Issue"). The exercise period for warrants series TO2 issued in conjunction with the Rights Issue begins on Monday, August 14, 2023. Each warrant series TO2 entitles to subscription of one (1) new share in the Company at an exercise price of SEK 0.66.

## **Summarized terms for warrants series TO2:**

**Exercise period:** August 14 – August 25, 2023.

**Issue size:** 8,595,531 warrants series TO2, which entitle to subscription of 8,595,531 shares. If all warrants are exercised, the Company will receive approximately SEK 5.7 million before issuing costs.

**Subscription price:** SEK 0.66 per share.

**Last day for trading warrants series TO2:** August 22, 2023.

**Share capital and dilution:** If all warrants are exercised, the share capital will increase with SEK 214,888.275, from SEK 1,060,691.500 to SEK 1,275,579.775, and the number of shares and votes in the Company will increase with 8,595,531, from 42,427,660 to 51,023,191. In the event that all warrants series TO2 are exercised, the dilution amounts to approximately 16.8 percent of the number of shares and votes in the Company.

Each unit in the Rights Issue consisted of five (5) shares and three (3) warrants series TO2. Each warrant series TO2 entitles to subscription of one (1) new share in the Company. The exercise price for warrants series TO2 has been determined as 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the measurement period, which ran from and including July 28, 2023, up to and including August 10, 2023. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 0.94, therefore, the exercise price for warrants series TO2 is SEK 0.66. The exercise period for warrants series TO2 runs during the period from and including August 14, 2023, up to and including August 25, 2023.

If all warrants series TO2 are exercised, the Company will receive approximately SEK 5.7 million before issuing costs. In order for the warrants not to expire and lose their value, it is required that the holder actively subscribes for new shares no later than August 25, 2023, or sells the warrants no later than August 22, 2023. Please observe that certain nominees might close their application earlier than August 25, 2023.

***Please note that warrants that are not exercised no later than August 25, 2023, or sold no later than August 22, 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.***

## **How warrants are exercised:**

### **Nominee-registered warrants (Custody account)**

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Note that the nominees need your notification of the exercise of warrants series TO2 in time before the end of the exercise period. Please contact your nominee for additional information. Observe that certain nominees might close their application earlier than August 25, 2023.

**Direct-registered warrants (Securities account)**

The warrant holders who have warrants series TO2 in a VP-account subscribe directly via an application form. The application form is then to be submitted via e-mail to [emissioner@mangold.se](mailto:emissioner@mangold.se) or by mail according to instructions on the application form. Please contact the institute where you have your warrants registered for additional information.

The application form including instructions for payment will be available at the Company's website, [www.Biosergen.net](http://www.Biosergen.net).

**Advisors**

Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to Biosergen in connection with the exercise of warrants series TO2.

**For further information about Biosergen, please contact:**

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470

E-mail: [peder.andersen@biosergen.net](mailto:peder.andersen@biosergen.net)

Niels Lauren, CFO

Telephone: +45 4014 5059

E-mail: [niels.laursen@biosergen.net](mailto:niels.laursen@biosergen.net)

**Certified Adviser**

Erik Penser Bank

Telephone: +46 8 463 8000

E-mail: [certifiedadvisor@penser.se](mailto:certifiedadvisor@penser.se)

**ABOUT BIOSERGEN**

Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to Phase II clinical trials expected to clinically validate BSG005's potential as a game-changing antifungal treatment. Biosergen's development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit [www.biosergen.net](http://www.biosergen.net).